Even after Eli Lilly missed its first swing at the lucrative U.S. market with ulcerative colitis drug mirikizumab, the company’s launch is gaining steam overseas. Friday, England’s National Institute ...
Thousands of people could be set to benefit after NICE today (Monday, 11 March) recommended a new one-a-day pill as an option for treating severe ulcerative colitis. NICE’s final guidance on etrasimod ...
A new once-a-day pill has been recommended as an option for treating severe ulcerative colitis in England, with thousands of patients set to be eligible. The move, on Monday, came on the same day that ...
Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: NICE response to consultee and commentator comments on the draft scope and provisional matrix (post-referral) Ulcerative colitis ...
The National Institute for Health and Care Excellence (NICE) has given its nod to etrasimod (Velsipity, Pfizer) a once-daily pill treatment option for severe ulcerative colitis. The recommendation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results